{ "items": [ "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n THE USE OF NEXT-GENERATION SEQUENCING TO SCREEN THE BRITISH POPULATION FOR DISORDERS OF IRON REGULATION USING A 16 GENE PANEL\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Ten novel mutations in the erythroid transcription factor KLF1 gene associated with increased fetal hemoglobin levels in adults.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Severe haemolysis due to passenger lymphocyte syndrome after an ABO mismatched bowel transplant--a case report.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Prevention of worsening of severe thrombocytopenia after red cell transfusions by the use of leucocyte-depleted blood.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n p53 Functional Assessment and Correlation with 17p Deletion and/or TP53 Mutation Status: Final Report of the ICLL001 Bomp Trial\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }